188 related articles for article (PubMed ID: 37302584)
1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
3. Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma.
Demir S; Razizadeh N; Indersie E; Branchereau S; Cairo S; Kappler R
Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285887
[TBL] [Abstract][Full Text] [Related]
4. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
5. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
Colyn L; Bárcena-Varela M; Álvarez-Sola G; Latasa MU; Uriarte I; Santamaría E; Herranz JM; Santos-Laso A; Arechederra M; Ruiz de Gauna M; Aspichueta P; Canale M; Casadei-Gardini A; Francesconi M; Carotti S; Morini S; Nelson LJ; Iraburu MJ; Chen C; Sangro B; Marin JJG; Martinez-Chantar ML; Banales JM; Arnes-Benito R; Huch M; Patino JM; Dar AA; Nosrati M; Oyarzábal J; Prósper F; Urman J; Cubero FJ; Trautwein C; Berasain C; Fernandez-Barrena MG; Avila MA
Hepatology; 2021 Jun; 73(6):2380-2396. PubMed ID: 33222246
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
8. Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma.
Wang H; Lu J; Edmunds LR; Kulkarni S; Dolezal J; Tao J; Ranganathan S; Jackson L; Fromherz M; Beer-Stolz D; Uppala R; Bharathi S; Monga SP; Goetzman ES; Prochownik EV
J Biol Chem; 2016 Dec; 291(51):26241-26251. PubMed ID: 27738108
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of
Beck A; Trippel F; Wagner A; Joppien S; Felle M; Vokuhl C; Schwarzmayr T; Strom TM; von Schweinitz D; Längst G; Kappler R
Clin Epigenetics; 2018; 10():27. PubMed ID: 29507645
[TBL] [Abstract][Full Text] [Related]
10. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
[TBL] [Abstract][Full Text] [Related]
11. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.
Thng DKH; Hooi L; Toh CCM; Lim JJ; Rajagopalan D; Syariff IQC; Tan ZM; Rashid MBMA; Zhou L; Kow AWC; Bonney GK; Goh BKP; Kam JH; Jha S; Dan YY; Chow PKH; Toh TB; Chow EK
Mol Oncol; 2023 Nov; 17(11):2275-2294. PubMed ID: 36896891
[TBL] [Abstract][Full Text] [Related]
12. Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Abril-Fornaguera J; Torrens L; Andreu-Oller C; Carrillo-Reixach J; Rialdi A; Balaseviciute U; Pinyol R; Montironi C; Haber PK; Del Río-Álvarez Á; Domingo-Sàbat M; Royo L; Akers NK; Willoughby CE; Peix J; Torres-Martin M; Puigvehi M; Cairo S; Childs M; Maibach R; Alaggio R; Czauderna P; Morland B; Losic B; Mazzaferro V; Guccione E; Sia D; Armengol C; Llovet JM
Mol Cancer Ther; 2023 Apr; 22(4):485-498. PubMed ID: 36780225
[TBL] [Abstract][Full Text] [Related]
13. Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells.
Eberherr C; Beck A; Vokuhl C; Becker K; Häberle B; Von Schweinitz D; Kappler R
Int J Oncol; 2019 May; 54(5):1853-1863. PubMed ID: 30864675
[TBL] [Abstract][Full Text] [Related]
14. MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.
Tu WB; Shiah YJ; Lourenco C; Mullen PJ; Dingar D; Redel C; Tamachi A; Ba-Alawi W; Aman A; Al-Awar R; Cescon DW; Haibe-Kains B; Arrowsmith CH; Raught B; Boutros PC; Penn LZ
Cancer Cell; 2018 Oct; 34(4):579-595.e8. PubMed ID: 30300580
[TBL] [Abstract][Full Text] [Related]
15. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.
Bárcena-Varela M; Caruso S; Llerena S; Álvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Rebouissou S; Alvarez L; Jimenez M; Santamaría E; Rodriguez-Ortigosa C; Mazza G; Rombouts K; San José-Eneriz E; Rabal O; Agirre X; Iraburu M; Santos-Laso A; Banales JM; Zucman-Rossi J; Prósper F; Oyarzabal J; Berasain C; Ávila MA; Fernández-Barrena MG
Hepatology; 2019 Feb; 69(2):587-603. PubMed ID: 30014490
[TBL] [Abstract][Full Text] [Related]
16. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
[TBL] [Abstract][Full Text] [Related]
17. G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer.
Pangeni RP; Yang L; Zhang K; Wang J; Li W; Guo C; Yun X; Sun T; Wang J; Raz DJ
Clin Epigenetics; 2020 Jun; 12(1):88. PubMed ID: 32552834
[TBL] [Abstract][Full Text] [Related]
18. Hepatoblastomas exhibit marked
Rivas MP; Aguiar TFM; Maschietto M; Lemes RB; Caires-Júnior LC; Goulart E; Telles-Silva KA; Novak E; Cristofani LM; Odone V; Cypriano M; de Toledo SRC; Carraro DM; Escobar MQ; Lee H; Johnston M; da Costa CML; da Cunha IW; Tasic L; Pearson PL; Rosenberg C; Timchenko N; Krepischi ACV
Tumour Biol; 2020 Dec; 42(12):1010428320977124. PubMed ID: 33256542
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation as a key epigenetic player for hepatoblastoma characterization.
Rivas M; Aguiar T; Fernandes G; Lemes R; Caires-Júnior L; Goulart E; Telles-Silva K; Maschietto M; Cypriano M; de Toledo S; Carraro D; da Cunha I; da Costa C; Rosenberg C; Krepischi A
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101684. PubMed ID: 33852955
[TBL] [Abstract][Full Text] [Related]
20. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL; Rodríguez TC; Mou H; Kwan SY; Pratt H; Zhang XO; Cao Y; Liang S; Ozata DM; Yu T; Yin Q; Hazeltine M; Weng Z; Sontheimer EJ; Xue W
Hepatology; 2021 Mar; 73(3):1011-1027. PubMed ID: 32452550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
